XENON PHARMACEUTICALS INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
XENON PHARMACEUTICALS INC. (XENE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $4.98 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $4.98M, a 46.18% decline year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $5.80M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$89.00K.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $9.33M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $24.29M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$47.84M, a 569.32% decline from fiscal 2015.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was $10.19M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$3.24M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $4.98M 10-Q · filed 2018-05-08 | $10.78M derived: sum of 2 quarters · filed 2018-05-08 | $10.69M derived: sum of 3 quarters · filed 2018-05-08 | $20.02M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $5.71M derived: sum of 2 quarters · filed 2018-03-07 | $15.05M derived: sum of 3 quarters · filed 2018-03-07 | $24.29M 10-K · filed 2018-03-07 |
| 2017-09-30 | -$89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $9.24M derived: sum of 2 quarters · filed 2017-11-07 | $18.49M 10-Q · filed 2017-11-07 | -$13.73M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-06-30 | $9.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $18.58M 10-Q · filed 2017-08-03 | -$13.65M derived: sum of 3 quarters · filed 2018-05-08 | -$13.76M derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-03-31 | $9.25M 10-Q · filed 2018-05-08 | -$22.98M derived: sum of 2 quarters · filed 2018-05-08 | -$23.09M derived: sum of 3 quarters · filed 2018-05-08 | -$38.51M derived: sum of 4 quarters · filed 2018-05-08 |
| 2016-12-31 | -$32.23M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$32.34M derived: sum of 2 quarters · filed 2018-03-07 | -$47.76M derived: sum of 3 quarters · filed 2018-03-07 | -$47.84M 10-K · filed 2018-03-07 |
| 2016-09-30 | -$111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$15.53M derived: sum of 2 quarters · filed 2017-11-07 | -$15.62M 10-Q · filed 2017-11-07 | -$15.76M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$15.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | -$15.51M 10-Q · filed 2017-08-03 | -$15.65M derived: sum of 3 quarters · filed 2018-03-07 | -$6.94M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$83.00K 10-Q · filed 2017-05-09 | -$226.00K derived: sum of 2 quarters · filed 2018-03-07 | $8.48M derived: sum of 3 quarters · filed 2018-03-07 | $8.62M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | -$143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $8.57M derived: sum of 2 quarters · filed 2018-03-07 | $8.70M derived: sum of 3 quarters · filed 2018-03-07 | $10.19M 10-K · filed 2018-03-07 |
| 2015-09-30 | $8.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $8.85M derived: sum of 2 quarters · filed 2016-11-03 | $10.34M 10-Q · filed 2016-11-03 | $11.38M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-06-30 | $137.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $1.63M 10-Q · filed 2016-08-03 | $2.67M derived: sum of 3 quarters · filed 2017-03-08 | -$2.74M derived: sum of 4 quarters · filed 2017-03-08 |
| 2015-03-31 | $1.49M 10-Q · filed 2016-05-10 | $2.53M derived: sum of 2 quarters · filed 2017-03-08 | -$2.88M derived: sum of 3 quarters · filed 2017-03-08 | -$1.42M derived: sum of 4 quarters · filed 2017-03-08 |
| 2014-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-08 | -$4.37M derived: sum of 2 quarters · filed 2017-03-08 | -$2.91M derived: sum of 3 quarters · filed 2017-03-08 | -$3.24M 10-K · filed 2017-03-08 |
| 2014-09-30 | -$5.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$3.95M derived: sum of 2 quarters · filed 2015-11-10 | -$4.28M 10-Q · filed 2015-11-10 | -$6.14M derived: sum of 4 quarters · filed 2016-03-08 |
| 2014-06-30 | $1.46M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2015-08-13 | $1.13M 10-Q · filed 2015-08-13 | -$729.00K derived: sum of 3 quarters · filed 2016-03-08 | |
| 2014-03-31 | -$338.00K 10-Q/A · filed 2015-08-13 | -$2.19M derived: sum of 2 quarters · filed 2016-03-08 | ||
| 2013-12-31 | -$1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$11.47M 10-K · filed 2016-03-08 | ||
| 2013-09-30 | -$9.62M 10-Q · filed 2014-12-15 | |||
| 2012-12-31 | $491.00K 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |